Literature DB >> 10749714

Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart.

J Sakamoto1, R L Barr, K M Kavanagh, G D Lopaschuk.   

Abstract

Myocardial glucose oxidation is markedly reduced in the uncontrolled diabetic. We determined whether this was due to direct biochemical changes in the heart or whether this was due to altered circulating levels of insulin and substrates that can be seen in the diabetic. Isolated working hearts from control or diabetic rats (streptozotocin, 55 mg/kg iv administered 6 wk before study) were aerobically perfused with either 5 mM [(14)C]glucose and 0.4 mM [(3)H]palmitate (low-fat/low-glucose buffer) or 20 mM [(14)C]glucose and 1.2 mM [(3)H]palmitate (high-fat/high-glucose buffer) +/-100 microU/ml insulin. The presence of insulin increased glucose oxidation in control hearts perfused with low-fat/low-glucose buffer from 553 +/- 85 to 1,150 +/- 147 nmol x g dry wt(-1) x min(-1) (P < 0. 05). If control hearts were perfused with high-fat/high-glucose buffer, palmitate oxidation was significantly increased by 112% (P < 0.05), but glucose oxidation decreased to 55% of values seen in the low-fat/low-glucose group (P < 0.05). In diabetic hearts, glucose oxidation was very low in hearts perfused with low-fat/low-glucose buffer (9 +/- 1 nmol x g dry wt(-1) x min(-1)) and was not altered by insulin or high-fat/high-glucose buffer. These results suggest that neither circulating levels of substrates nor insulin was responsible for the reduced glucose oxidation in diabetic hearts. To determine if subcellular changes in the control of fatty acid oxidation contribute to these changes, we measured the activity of three enzymes involved in the control of fatty acid oxidation; AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC), and malonyl-CoA decarboxylase (MCD). Although AMPK and ACC activity in control and diabetic hearts was not different, MCD activity and expression in all diabetic rat heart perfusion groups were significantly higher than that seen in corresponding control hearts. These results suggest that an increased MCD activity contributes to the high fatty acid oxidation rates and reduced glucose oxidation rates seen in diabetic rat hearts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749714     DOI: 10.1152/ajpheart.2000.278.4.H1196

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  20 in total

Review 1.  Protein acetylation in metabolism - metabolites and cofactors.

Authors:  Keir J Menzies; Hongbo Zhang; Elena Katsyuba; Johan Auwerx
Journal:  Nat Rev Endocrinol       Date:  2015-10-27       Impact factor: 43.330

Review 2.  Metabolic alterations induce oxidative stress in diabetic and failing hearts: different pathways, same outcome.

Authors:  David Roul; Fabio A Recchia
Journal:  Antioxid Redox Signal       Date:  2015-04-30       Impact factor: 8.401

3.  Parallel effects of β-adrenoceptor blockade on cardiac function and fatty acid oxidation in the diabetic heart: Confronting the maze.

Authors:  Vijay Sharma; John H McNeill
Journal:  World J Cardiol       Date:  2011-09-26

Review 4.  Metabolic enzymes dysregulation in heart failure: the prospective therapy.

Authors:  Priyanka Parihar; Mordhwaj Singh Parihar
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

Review 5.  Metabolic abnormalities in the diabetic heart.

Authors:  Gary D Lopaschuk
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

Review 6.  Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation.

Authors:  Karalyn D Cuthbert; Jason R B Dyck
Journal:  Curr Hypertens Rep       Date:  2005-12       Impact factor: 5.369

Review 7.  Metabolic dysfunction in diabetic cardiomyopathy.

Authors:  Michael Isfort; Sarah C W Stevens; Stephen Schaffer; Chian Ju Jong; Loren E Wold
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

Review 8.  Disruption of energy utilization in diabetic cardiomyopathy; a mini review.

Authors:  Shinsuke Nirengi; Carmem Peres Valgas da Silva; Kristin I Stanford
Journal:  Curr Opin Pharmacol       Date:  2020-09-25       Impact factor: 5.547

9.  Dietary supplementation with vitamin E ameliorates cardiac failure in type I diabetic cardiomyopathy by suppressing myocardial generation of 8-iso-prostaglandin F2alpha and oxidized glutathione.

Authors:  Milton Hamblin; Holly M Smith; Michael F Hill
Journal:  J Card Fail       Date:  2007-12       Impact factor: 5.712

10.  Augmented cardiac formation of oxidatively-induced carbonylated proteins accompanies the increased functional severity of post-myocardial infarction heart failure in the setting of type 1 diabetes mellitus.

Authors:  Kathleen E Dennis; Salisha Hill; Kristie L Rose; Uchechukwu K A Sampson; Michael F Hill
Journal:  Cardiovasc Pathol       Date:  2013-04-06       Impact factor: 2.185

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.